McKesson Corporation is an American company distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools.
| Revenue (TTM) | $410.98B |
| Gross Profit (TTM) | $14.93B |
| EBITDA | $7.07B |
| Operating Margin | 1.35% |
| Return on Equity | 0.00% |
| Return on Assets | 4.74% |
| Revenue/Share (TTM) | $3367.33 |
| Book Value | $-36.55 |
| Price-to-Book | 5.04 |
| Price-to-Sales (TTM) | 0.28 |
| EV/Revenue | 0.27 |
| EV/EBITDA | 19.63 |
| Quarterly Earnings Growth (YoY) | -17.60% |
| Quarterly Revenue Growth (YoY) | 7.70% |
| Shares Outstanding | $116.59M |
| Float | $116.40M |
| % Insiders | 0.06% |
| % Institutions | 93.72% |
Volatility is currently contracting
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is how McKesson (MCK) and Avantor, Inc. (AVTR) have performed compared to their sector so far this year.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
In the closing of the recent trading day, McKesson (MCK) stood at $910.33, denoting a -1.23% move from the preceding trading day.
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Mckesson Corp (NYSE:MCK), the US healthcare services and drug distribution company, and Clayton Dubilier & Rice (CD&R), the private investment firm, have agreed to acquire Option Care Health (NASDAQ:OPCH) for approximately $5.8 billion. The buyers will pay $32.05 a share for Option Care Health, the largest independent provider of home and alternate-site infusion services in the US, representing a 37% premium to Monday's closing price.
Under the agreement, CD&R will hold a majority interest of about 51% in Option Care Health, while McKesson will hold about 49%.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MCK and any ticker you trade — then tracks every position and per-strategy win rate.
